TScan Therapeutics, Inc.
TCRX· Nasdaq
TCRXTScan Therapeutics, Inc.
Filed Mar 8, 2023 · 10-K · 67 days after period end · 0000950170-23-006589
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|
| Revenue | $3.10M | $2.85M | — |
| Net Income | -$18.72M | -$14.20M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Mar 8, 2023 · 67 d after period end
